Unicycive Therapeutics, Inc. (UNCY)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (7.3M) | (7.2M) | (8.4M) | (10.1M) |
| Net Income | (6.0M) | (14.7M) | (12.8M) | (1.7M) |
| Diluted EPS | $-0.33 | N/A | $-0.54 | $-0.06 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 951K | 675K | 0.00 | 0.00 |
| Operating Income | (18.1M) | (20.8M) | (32.1M) | (29.5M) |
| Net Income | (18.1M) | (30.5M) | (36.7M) | (26.6M) |
| Diluted EPS | $-12.00 | $-12.80 | $-5.65 | $-1.67 |